These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 24757248)

  • 1. Tyrosine kinase inhibitor sunitinib allows insulin independence in long-standing type 1 diabetes.
    Huda MS; Amiel SA; Ross P; Aylwin SJ
    Diabetes Care; 2014; 37(5):e87-8. PubMed ID: 24757248
    [No Abstract]   [Full Text] [Related]  

  • 2. Use of sunitinib in a 30-year-old woman with pancreatic neuroendocrine tumors associated with Von Hippel-Lindau syndrome.
    Wang W; Jiang CY; Wang HW
    J Clin Gastroenterol; 2015 Jan; 49(1):89-90. PubMed ID: 24921213
    [No Abstract]   [Full Text] [Related]  

  • 3. Life-threatening hypoglycemia induced by a tyrosine kinase inhibitor in a patient with neuroendocrine tumor: a case report.
    Lee Y; Jung HS; Choi HJ; Kim MJ; Kim TM; Park KS; Kim SY
    Diabetes Res Clin Pract; 2011 Aug; 93(2):e68-e70. PubMed ID: 21565416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.
    Raymond E; Dahan L; Raoul JL; Bang YJ; Borbath I; Lombard-Bohas C; Valle J; Metrakos P; Smith D; Vinik A; Chen JS; Hörsch D; Hammel P; Wiedenmann B; Van Cutsem E; Patyna S; Lu DR; Blanckmeister C; Chao R; Ruszniewski P
    N Engl J Med; 2011 Feb; 364(6):501-13. PubMed ID: 21306237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice.
    Agostino NM; Chinchilli VM; Lynch CJ; Koszyk-Szewczyk A; Gingrich R; Sivik J; Drabick JJ
    J Oncol Pharm Pract; 2011 Sep; 17(3):197-202. PubMed ID: 20685771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sunitinib and improved diabetes control.
    Tyrrell HE; Pwint T
    BMJ Case Rep; 2014 Dec; 2014():. PubMed ID: 25540214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Promising advances in the treatment of malignant pancreatic endocrine tumors.
    Jensen RT; Delle Fave G
    N Engl J Med; 2011 Feb; 364(6):564-5. PubMed ID: 21306243
    [No Abstract]   [Full Text] [Related]  

  • 8. Advances in pancreatic neuroendocrine tumor treatment.
    Berruti A; Pia A; Terzolo M
    N Engl J Med; 2011 May; 364(19):1871-2; author reply 1873-4. PubMed ID: 21561357
    [No Abstract]   [Full Text] [Related]  

  • 9. Targeted therapies: Good news for advanced-stage pancreatic neuroendocrine tumors.
    Spiegel AM; Libutti SK
    Nat Rev Clin Oncol; 2011 May; 8(5):258-9. PubMed ID: 21448150
    [No Abstract]   [Full Text] [Related]  

  • 10. Insulin analogues for recurrent severe hypoglycaemia.
    Knip M
    Lancet Diabetes Endocrinol; 2014 Jul; 2(7):529-30. PubMed ID: 24794702
    [No Abstract]   [Full Text] [Related]  

  • 11. Circulating biomarkers of response to sunitinib in gastroenteropancreatic neuroendocrine tumors: current data and clinical outlook.
    Mateo J; Heymach JV; Zurita AJ
    Mol Diagn Ther; 2012 Jun; 16(3):151-61. PubMed ID: 22515658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Severe resistant hypoglycemia in a patient with a pancreatic neuroendocrine tumor on sunitinib treatment.
    Fountas A; Tigas S; Giotaki Z; Petrakis D; Pentheroudakis G; Tsatsoulis A
    Hormones (Athens); 2015; 14(3):438-41. PubMed ID: 25553766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sunitinib for advanced pancreatic neuroendocrine tumors.
    Hubner RA; Valle JW
    Expert Rev Anticancer Ther; 2011 Dec; 11(12):1817-27. PubMed ID: 22117148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of fast-acting insulin aspart compared with insulin aspart in combination with insulin degludec in Japanese adults with type 1 diabetes: a subgroup analysis of the randomized onset 8 trial.
    Komatsu M; Ekelund M; Horio H; Kadowaki T
    Endocr J; 2021 Apr; 68(4):429-440. PubMed ID: 33390422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Remission of diabetes while on sunitinib treatment for renal cell carcinoma.
    Templeton A; Brändle M; Cerny T; Gillessen S
    Ann Oncol; 2008 Apr; 19(4):824-5. PubMed ID: 18326519
    [No Abstract]   [Full Text] [Related]  

  • 16. New treatments of pancreatic neuroendocrine tumors: why using them? How to use them?
    Raymond E; Ruszniewski P
    Target Oncol; 2012 Jun; 7(2):91-2. PubMed ID: 22669625
    [No Abstract]   [Full Text] [Related]  

  • 17. Severe perirenal hematoma in a patient with a single kidney treated with sunitinib for metastatic pancreatic neuroendocrine tumor.
    Zugazagoitia J; Sastre J; Barrera J; García B; Díaz-Rubio E
    J Cancer Res Ther; 2012; 8(2):303-5. PubMed ID: 22842382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive Markers of Response to Everolimus and Sunitinib in Neuroendocrine Tumors.
    Martins D; Spada F; Lambrescu I; Rubino M; Cella C; Gibelli B; Grana C; Ribero D; Bertani E; Ravizza D; Bonomo G; Funicelli L; Pisa E; Zerini D; Fazio N;
    Target Oncol; 2017 Oct; 12(5):611-622. PubMed ID: 28634872
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sunitinib in pancreatic neuroendocrine tumors.
    Raymond E; Hammel P; Dreyer C; Maatescu C; Hentic O; Ruszniewski P; Faivre S
    Target Oncol; 2012 Jun; 7(2):117-25. PubMed ID: 22661319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ideglira is Associated With Improved Short-Term Clinical Outcomes and Cost Savings Compared with Insulin Glargine U100 Plus Insulin Aspart in the U.S.
    Dempsey M; Mocarski M; Langer J; Hunt B
    Endocr Pract; 2018 Sep; 24(9):796-804. PubMed ID: 30308134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.